Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad

Evaluation of SinaCurcumin as a complementary therapy in mild to moderate COVID-19: An open label non-randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200408046990N1

Enrollment

Registered

2020-04-18

Start date

2020-05-19

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: nanocurcumin capsule 40mg, two capsule twice daily for two weeks then 1 capsule twice daily for 2 weeks. Intervention 2: Control group:all standard measures will be

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: laboratory or radiologic or clinical diagnosis of mild to moderate COVID-19 age between 18-65y sign of the written consent Not simultaneous participating in other clinical trials

Exclusion criteria

Exclusion criteria: more than 7d from the beginning of the symptoms pregnancy or lactation history of allergy to curcumin or turmeric smoking (more than 5 cigarettes per day) complicated concomitant bacterial infection adverse drug reaction occurrence SaO2<90% past medical diseases (e.g. kidney, hepatic, heart failure, complicated heart or brain disease, diabetes, chronic lung disease, malignancies, endocrine diseases, any immune system dysfunction like AIDS) history of gallbladder history of active GI ulcer

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on clinical, paraclinical and laboratory findings.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient interview and file.;Radiologic response. Timepoint: one month after the beginning of the treatment. Method of measurement: lung HRCT.	—

Measure

Time frame

Fever. Timepoint: daily. Method of measurement: thermometer.;Clinical response to treatment (including improvement of cough, myalgia, headache, Olfactory and taste disorders). Timepoint: daily. Method of measurement: Based on clinical, paraclinical and laboratory findings.;Drug adverse reaction. Timepoint: daily. Method of measurement: patient interview and file.;Radiologic response. Timepoint: one month after the beginning of the treatment. Method of measurement: lung HRCT.

—

Secondary

Measure	Time frame
Length of hospital stay. Timepoint: at the end of treatment course. Method of measurement: patient file.;Patient clinical outcome. Timepoint: at the end of the treatment. Method of measurement: patient file.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Elyasi

Mashhad University of Medical Sciences

elyasis@mums.ac.ir+98 51 3180 1588

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026